A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents

Health Policy

Volumn 119, Issue 6, 2015, Pages 802-813

  Chiu, Yunwen ^a   Bero, Lisa ^a   Hessol, Nancy A ^a   Lexchin, Joel ^b   Harrington, Charlene ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b YORK UNIVERSITY   (Canada)

Author keywords

Adverse effects; Antipsychotic agents; Nursing home; Outcome assessment; Policy

Indexed keywords

ACETOPHENAZINE; ARIPIPRAZOLE; CHLORPROMAZINE; CHLORPROTHIXENE; CLORAZEPATE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MESORIDAZINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PROCHLORPERAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; ZIPRASIDONE; ZUCLOPENTHIXOL;

ACCIDENTAL INJURY; BACTERIAL INFECTION; BEHAVIOR DISORDER; CEREBROVASCULAR ACCIDENT; CONVULSION; DEMENTIA; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HIP FRACTURE; HOME CARE; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; NURSING HOME; NURSING HOME PATIENT; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; URINE INCONTINENCE; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; RISK FACTOR; UNITED STATES;

ANTIPSYCHOTIC AGENTS; DEMENTIA; HUMANS; NURSING HOMES; OFF-LABEL USE; RISK FACTORS; UNITED STATES;

EID: 84930083076     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2015.02.014     Document Type: Review

References (65)

1. Murman D.L., Chen Q., Powell M.C., Kuo S.B., Bradley C.J., Colenda C.C. The incremental direct costs associated with behavioral symptoms in AD. Neurology 2002, 59(11):1721-1729.
2. Feng Z., Hirdes J.P., Smith T.F., Finne-Soveri H., Chi I., Du Pasquier J.-N., et al. Use of physical restraints and antipsychotic medications in nursing homes: a cross-national study. International Journal of Geriatric Psychiatry 2009, 24(10):1110-1118.
3. Chen Y., Breisacher B.A., Field T.S., Tjia J., Lau D.T., Gurwitz J.H. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Archives of Internal Medicine 2010, 170(1):89-95.
4. Hillmer M.P., Wodchis W.P., Gill S.S., Anderson G.M., Rochon P.A. Nursing home profit status and quality of care: is there any evidence of an association?. Medical Care Research and Review 2005, 62:139-166.
5. Kolanowski A., Fick D., Frazer C., Penrod J. It's about time: use of nonpharmacological interventions in the nursing home. Journal of Nursing Scholarship 2010, 42(2):214-222.
6. Bonner A. Improving dementia care and reducing unnecessary antipsychotic medications in nursing homes. Medicare learning network presentation 2013, vol. 31:2013.
7. Christian R., Saavedra L., Gaynes B.N., Sheitman B., Wines R.C., Jonas D.E., et al. Future research needs for first- and second-generation antipsychotics children and young adults-Apendix A 2012, Agency for Healthcare and Research, Rockville, MD.
8. Arana G.W. An overview of side effects caused by typical antipsychotics. Journal of Clinical Psychiatry 2000, 61(suppl 8):5-11.
9. Kamble P., Chen H., Sherer J.T., Aparasu R.R. Use of antispychotics among elderly nursing home residents with dementia in the US. Drugs & Aging 2009, 26(6):483-492.
10. AHRQ Efficacy and comparative effectiveness of off-label use of atypical antipsychotics (07-EHCOO3-EF). Comparative effectiveness reviews no 43 Jan, 2007, AHRQ, Rockville, MD.
11. Gareri P., De Fazio P., De Fazio S., Marigliano N., Ferreri Ibbadu G., De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs & Aging 2006, 23(12):937-956.
12. Maher A.R., Maglione M., Bagley S., Suttorp M., Hu J.H., Ewing B., et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. Journal of the American Medical Association 2011, 306(12):1359-1369.
13. Schneider L.S., Dagerman K.S., Insel P. Risk of Death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association 2005, 294(15):1934-1943.
14. Food Drug Administration (FDA) FDA requests new boxed warnings on older class of antipsychotic drugs 2008, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm (accessed on Aug 15, 2012).
15. Trifirò G., Spina E., Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile?. Pharmacological Research 2009, 59(1):1-12.
16. Albert S.G., Grossberg G.T., Thaipisuttikul P.J., Scouby J., Green E. Atypical antipsychotics and the risk of diabetes in an elderly population in long-term care: a retrospective nursing home chart review study. Journal of the American Medical Directors Association 2009, 10(2):115-119.
17. Kamble P., Sherer J., Chen H., Aparasu R. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatric Services 2010, 61(2):130-136.
18. Lester P., Kohen I., Stefanacci R.G., Feuerman M. Antipsychotic drug use since the FDA black box warning: survey of nursing home policies. Journal of the American Medical Directors Association 2011, 12(8):573-577.
19. Department of Health and Human Services, Office of Inspector General Medicare atypical antipsychotic drug claims for elderly nursing home residents. OEI-07-08-00150 May, 2011.
20. Brodaty H., Arasaratnam C. Meta-analysis of nonpharmacological interventions for neuropsychiatric symptoms of dementia. American Journal of Psychiatry 2012, 169:946-953.
21. Cohen-Mansfield J. Nonpharmacologic treatment of behavioral disorders in dementia. Current Treatment Options in Neurology 2013, 15(6):765-785.
22. Devanand D.P. Psychosis, agitation, and antipsychotic treatment in dementia. American Journal of Psychiatry 2013, 170(9):957-960.
23. Omnibus Budget Reconciliation Act of 1990. OBRA-90; Pub.L. 101-508, 104 Stat. 1388, enacted November 5, 1990.
24. F-329 - Free from Unnecessary Drugs. 42 C.F.R. Rev§483.25 (1)(2).
25. CMS. Description of Antipsychotic Medication Quality Measures on Nursing Home Compare. http://www.cms.gov/Medicare/Provider-Enrollment-and-Certification/CertificationandComplianc/Downloads/AntipsychoticMedicationQM.pdf (Accessed 9/03/2012).
26. CMS.gov National partnership to improve dementia care exceeds goal to reduce use of antipsychotic medications in nursing homes: CMS announces new goal 2014, http://www.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2014-Press-releases-items/2014-09-19.html (accessed 10/16/14).
27. CMS National partnership to improve dementia care exceeds goal to reduce use of antipsychotic medications in nursing homes: CMS announces new goal 2014, http://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2014-Fact-sheets-items/2014-09-19.html (accessed 10/22/14).
28. Lundh A., Sismondo S., Lexchin J., Busuioc O.A., Bero L. Industry sponsorship and research outcome. Cochrane Database Systematic Review 2012, 12:MR000033.
29. Pawson R., Greenhalgh T., Harvey G., Walshe K. Realist review-a new method of systematic review designed for complex policy interventions. Journal of Health Services Research & Policy 2005, 10(suppl. 1):21-34.
30. Bronskill S.E., Rochon P.A., Gill S.S., Herrmann N., Hillmer M.P., Bell C.M., et al. The relationship between variations in antipsychotic prescribing across nursing homes and short-term mortality. Medical Care 2009, 47:1000-1008.
31. Etminan M., Streiner E.L., Rochon P.A. Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults. Pharmacotherapy 2003, 23(11):1411-1415.
32. Gill S.S., Bronskill S.E., Normand S.L., Anderson G.M., Sykora K., Lam K., et al. Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine 2007, 146:775-786.
33. Rochon P.A., Normand S.L., Gomes T., Gill S.S., Anderson M., Melo M., et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Archives of Internal Medicine 2008, 168(10):1090-1096.
34. Mintzer J.E., Tune L.E., Breder C.D., Swanink R., Marcus R.N., McQuede R.D., et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer Dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. The American Journal of Geriatric Psychiatry 2007, 15(11):918-931.
35. Schneeweiss S., Setoguchi S., Brookhart A., Dormuth C., Wang P.S. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Canadian Medical Association Journal 2007, 176(5):627-632.
36. Simoni-Wastila L., Ryder P.T., Qian J., Zuckerman I.H., Shaffer T., Zhao L. Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. American Journal of Geriatric Psychiatry 2009, 17(5):417-427.
37. Wang P.S., Schneeweiss S., Avorn J., Fischer M.A., Mogun H., Solomon D.H., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine 2005, 353(22):2335-2341.
38. Gurevitz S.L., Costakis T., Leiter J. Do atypical antipsychotics cause weight gain in nursing home dementia residents?. Journal of the American Society of Consultant Pharmacist 2004, 19:809-812.
39. Jalbert J.J., Daiello L.A., Eaton C.B., Miller S.C., Lapane K.L. Antipsychotic use and the risk of diabetes in nursing home residents with dementia. The American Journal of Geriatric Pharmacotherapy 2011, 9(3):153-163.
40. Jalbert J.J., Eaton C.B., Miller S.C., Lapane K.L. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. Journal of the American Medical Directors Association 2010, 11(2):120-127.
41. Liperoti R., Onder G., Lapane K.L., Mor V., Friedman J.H., Bernabei R., et al. Conventional or atypical antipsychotics and the risk of femur fractures among elderly patients: results of a case control study. Journal of Clinical Psychiatry 2007, 68:929-934.
42. Huybrechts K.F., Schneeweiss S., Gerhard T., Olfson M., Avorn J., Levin R., et al. Comparative safety of antipsychotic medications in nursing home residents. Journal of the American Geriatrics Society 2012, 60(3):420-429.
43. Liperoti R., Onder G., Landi F., Lapane K.L., Mor V., Bernabei R., et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. Journal of Clinical Psychiatry 2009, 70(10):1340-1347.
44. Huybrechts K.F., Gerhard T., Crystal S., Olfson M., Avorn J., Levin R., et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012, 334:e977.
45. Mintzer J., Greenspan A., Caers I., Van Hove I., Kushner S., Weiner M., et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. The American Journal of Geriatric Psychiatry 2006, 14(3):280-291.
46. Streim J.E., Portsteinsson A.P., Breder C.D., Swanink R., Marcus R., McQuede R., et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer Dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. The American Journal of Geriatric Psychiatry 2008, 16(7):537-550.
47. Tariot P.N., Schneider L., Katz I.R., Mintzer J.E., Street J., Copenhaver M., et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo0coontrolled clinical trial. American Journal of Geriatric Psychiatry 2006, 14(9):767-776.
48. Zhong K.X., Tariot P.N., Mintzer J., Minkwitz M.C., Devine N.A. Quetiapine to treat agitation in dementia: a randomized, placebo-controlled, double-blind study. Current Alzheimer Research 2007, 4(1):81-93.
49. Frenchman J.B. Atypical antipsychotics for nursing home patients: a retrospective chart review. Drugs & Aging 2005, 22(3):257-264.
50. Martin H., Slyk M.P., Deymann S., Cornacchione M.J. Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia. Journal of the American Medical Directors Association 2003, 4(4):183-188.
51. Liperoti R., Gambassi G., Lapane K.L., Chiang C., Pedone C., Mor V., et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. Journal of Clinical Psychiatry 2005, 66(9):1090-1096.
52. Liperoti R., Gambassi G., Lapane K.L., Chiang C., Pedone C., Mor V., et al. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest. Archives of Internal Medicine 2005, 165(6):696-701.
53. Liperoti R., Pedone C., Lapane K.L., Mor V., Bernabei R., Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Archives of Internal Medicine 2005, 165:2677-2682.
54. Schneeweiss S., Setoguchi S., Brookhart A., Dormuth C., Wang P.S. Comparative safety of conventional and atypical antipsychotic medications: risk of death in British Columbia seniors. Effective healthcare research report number 2 August, 2007.
55. Setoguchi S., Wang P.S., Brookhart M.A., Canning C.F., Kaci L., Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. Journal of the American Geriatric Society 2008, 56(9):1644-1650.
56. AHRQ Off-label use of atypical antipsychotics: an update (11-EHC087-EF). Comparative effectiveness reviews no 43 Sept, 2011, AHRQ, Rockville, MD.
57. Bolton J.M., Metge C., Lix L., Prior H., Sareen J., Leslie W.D. Fracture risk from psychotropic medications: a population-based analysis. Journal of Psychopharmacotherapy 2008, 28(4):284-391.
58. Oderda L.H., Young J.R., Asche C.V., Pepper G.A. Psychotropic related hip fractures: meta-analysis of first-generation and second-generation antidepressants and antipsychotic drugs. Annals of Pharmacotherapy 2012, 46(7-8):917-928.
59. American Geriatric Society Guide to the management of psychotic disorders and neuropsychiatric symptoms of dementia in older adults 2012, http://dementia.americangeriatrics.org/GeriPsych_index.php (accessed June 21, 2013).
60. Callahan C.M., Boustani M.A., Unverzagt F.W., Austrom M.G., Damush T.M., Perkins A.J., et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. Journal of American Medical Association 2006, 295(18):2148-2157.
61. Chrisholm-Burns M.A., Kim Lee J., Spivey C.A., Slack M., Herrier R.N., Hall-Lipsy E., et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Medical Care 2010, 48(10):923-933.
62. Giberson S., Yoder S., Lee M.P. Improving patient and health system outcomes through advanced pharmacy practice. A report to the U.S. surgeon general Dec, 2011, Office of the Chief Pharmacist. U.S. Public Health Service.
63. IOM Retooling for an aging America: building the health care workforce 2008, (Report briefing).
64. Hess D.R. Retrospective studies and chart reviews. Respiratory Care 2004, 49(10):1171-1174.
65. Ward R.A., Brier M.E. Retrospective analyses of large medical databases: what do they tell us?. Journal of the American Society of Nephrology 1998, 10(2):429-432.